Aradigm Corp. (NASDAQ:ARDM) has received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.
Brokerages have set a twelve-month consensus target price of $26.00 for the company, according to Zacks. Zacks has also assigned Aradigm Corp. an industry rank of 97 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research raised shares of Aradigm Corp. from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research report on Wednesday, August 24th.
A hedge fund recently raised its stake in Aradigm Corp. stock. Paulson & CO. Inc. raised its position in Aradigm Corp. (NASDAQ:ARDM) by 235.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 65,903 shares of the company’s stock after buying an additional 46,241 shares during the period. Paulson & CO. Inc. owned 0.45% of Aradigm Corp. worth $288,000 at the end of the most recent quarter. 44.27% of the stock is owned by hedge funds and other institutional investors.
Aradigm Corp. (NASDAQ:ARDM) opened at 6.50 on Wednesday. The company’s market cap is $96.08 million. The company’s 50 day moving average is $4.77 and its 200-day moving average is $4.52. Aradigm Corp. has a 12 month low of $2.60 and a 12 month high of $7.40.
Aradigm Corp. (NASDAQ:ARDM) last posted its quarterly earnings results on Wednesday, August 10th. The company reported ($0.59) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.59). Aradigm Corp. had a negative net margin of 670.67% and a negative return on equity of 147.53%. On average, analysts expect that Aradigm Corp. will post ($1.92) earnings per share for the current fiscal year.
About Aradigm Corp.
Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aradigm Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm Corp. and related companies with MarketBeat.com's FREE daily email newsletter.